| Autor: |
K. S. Skrupskiy, K. B. Kolontarev, A. V. Govorov, V. V. Dyakov, A. M. Lukin, B. I. Dzhumabaev, D. Yu. Pushkar |
| Jazyk: |
ruština |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Vestnik Urologii, Vol 12, Iss 4, Pp 82-90 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2308-6424 |
| DOI: |
10.21886/2308-6424-2024-12-4-82-90 |
| Popis: |
Introduction. The clinical guidelines recommend performing extended pelvic lymph node dissection for patients with intermediateor high-risk cancer prostate. The incidence of lymphocele development reaches 10.3%.Objective. The aim of this study was to evaluate the efficiency of the drug Lymphoblock after radical prostatectomy with pelvic lymphadenectomy.Materials & methods. The study involved 79 patients with prostate cancer who underwent robot-assisted radical prostatectomy with pelvic lymphadenectomy, that were randomized into three treatment groups: 1. Patients with free peritoneal flap fixed to the pubic bone (n = 26); 2. Patients who received Lymphoblock: during the surgery (n = 26); 3. Control group (n = 27). The median follow-up was 180 d.Results. In postoperative period lymphocele was diagnosed in 8 (10.1%) patients: group 1 — 2 (7.7%) patients, group 2 — 1 (3.8%), group 3 — 5 (18.5%). Lymphocele had no clinical manifestation in group patients who received Lymphoblock.Conclusions. Preliminary results of Lymphobloc use indicate that it can reduce the incidence of lymphogenic complications in the postoperative period in patients undergoing robot-assisted radical prostatectomy with pelvic lymphadenectomy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
